Albor Biotech

Preclinical Contract Research Organization (CRO) specializes in drug development process from early screening. Our aim is to assist pharmaceutical, biotechnology and nutraceutical companies, along with research laboratories, in optimizing preclinical drug candidate studies. By doing so, we endeavor to significantly decrease both the cost and time to market for new therapies. Over a span exceeding 15 years, we have been developing and using our expertise in metabolic diseases and behavior mechanisms, leveraging it to deliver reliable preclinical studies targeting a spectrum of pathologies, such as obesity, diabetes, NASH/MASH fibrosis, inflammation, oxidative stress, and conditions influencing behavior. In this way, we carry out a wide range of tests to demonstrate the effectiveness of our clients’ drug candidates.